Leiomyosarcoma Clinical Trials 2024

Leiomyosarcoma Clinical Trials 2024

Leiomyosarcoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in leiomyosarcoma clinical trials today.

Trials for LMS Patients

Trials for Soft Tissue Leiomyosarcoma Patients

Trials for Metastatic Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to leiomyosarcoma

What are the top hospitals conducting leiomyosarcoma research?

In the realm of clinical trials for leiomyosarcoma, several esteemed hospitals are making significant strides in advancing treatment options for this rare form of cancer. One such institution is the University of Colorado Hospital located in Aurora. With four active leiomyosarcoma trials and a history that includes six completed studies, this hospital has been dedicated to tackling this challenging disease since its first recorded trial in 2012. Meanwhile, at Tampa's Moffitt Cancer Center, researchers are also conducting four ongoing clinical trials focused on leiomyosarcoma, building upon their initial trial recorded in 2014.

Moving north to Chicago, Northwestern University is actively engaged with four ongoing leiomyosarcoma trials as part of their impressive track record that encompasses nine previous investigations dating back to 1992. Over at Memorial Sloan Kettering Cancer Center in New york City, a renowned medical facility globally recognized for its expertise, there are currently four active clinical trials targeting leiomyosarcoma while having conducted ten prior studies since recording their inaugural trial in 2001.

Lastly but notably not least UPMC based out Pittsburgh plays an important role as well; they have three ongoing examinations related to treating patients diagnosed with Leiomyoasracoma which displays strong dedication towards innovating more efficient solutions as these numbers add up alongside two earlier experiments registered only recently around until 2017.

Through the combined efforts of these reputable hospitals across different regions within the United States lies hope for individuals affected by leiomyosarcoma - a testament to how diverse healthcare institutions can unite under one purpose: improving outcomes and quality of life for those battling against this uncommon yet formidable form of cancer.

Which are the best cities for leiomyosarcoma clinical trials?

When it comes to leiomyosarcoma clinical trials, several cities emerge as top contenders for groundbreaking research opportunities. New york leads the pack with 17 active trials investigating treatments like Unesbulin, Dose Expansion Dose Level C (Cohort C), and VMD-928. Los Angeles follows closely behind with 11 ongoing studies focused on Doxorubicin, Unesbulin, Tabelecleucel, and other innovative approaches. Boston and Chicago also shine in this field, each boasting 11 active trials examining various treatment options such as Pembrolizumab and Lurbinectedin. Lastly, Jacksonville holds promise with its own set of 10 active trials exploring potential breakthroughs like L19TNF plus doxorubicin. These cities provide individuals battling leiomyosarcoma access to cutting-edge clinical trials that may shape the future of care for this disease.

Which are the top treatments for leiomyosarcoma being explored in clinical trials?

Clinical trials for leiomyosarcoma have showcased several promising treatments in recent years. Leading the pack is nivolumab, currently being explored in two active trials and making its debut in 2015. Also gaining traction is unesbulin, with one ongoing trial and two all-time leiomyosarcoma studies since its introduction in 2019. Rounding out this list is tabelecleucel, a newcomer on the scene that has already generated excitement with one active trial and a single all-time study since its listing in 2021. These innovative therapies are bringing renewed hope to patients fighting against leiomyosarcoma, paving the way towards more effective treatment options.

What are the most recent clinical trials for leiomyosarcoma?

Exciting advancements are being made in the field of leiomyosarcoma research, with several recent clinical trials offering potential treatment options for patients. One such trial focuses on unesbulin, a promising drug being evaluated in both Phase 2 and Phase 3 studies. Another trial examines the effectiveness of olaparib and temozolomide in treating leiomyosarcoma. Additionally, lurbinectedin is undergoing Phase 1 and Phase 2 testing to assess its potential benefits for patients with this type of sarcoma. Nanatinostat and OR2805 are also being investigated through combined Phase 1 and Phase 2 trials as possible treatments for leiomyosarcoma. These ongoing endeavors provide hope for improved outcomes and better quality of life for individuals battling this challenging disease.

What leiomyosarcoma clinical trials were recently completed?

Two recent clinical trials have brought valuable insights in the field of leiomyosarcoma research. In March 2017, OHSU Knight Cancer Institute conducted a pharmacological study to explore potential treatment options for this rare cancer. Another significant trial sponsored by Washington University School of Medicine investigated the use of Dexrazoxane and was completed in February 2016. These studies contribute to our understanding of leiomyosarcoma and pave the way for further advancements in its management and care.